NCT04305548 - Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

August 1, 2025

Study Completion Date

December 1, 2025

Conditions

Mesenchymal Chondrosarcoma

Interventions

DRUG

Trabectedin

Treatment with trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion

Trial Locations (7)

10060

RECRUITING

Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo

20133

RECRUITING

Fondazione IRCSS Istituto Nazionale dei Tumori, Milan

40136

RECRUITING

Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna

59100

RECRUITING

Nuovo Ospedale di Prato, Prato

00128

NOT_YET_RECRUITING

Policlinico Universitario Campus Biomedico, Roma

RECRUITING

Istituti Fisioterapici Ospitalieri - Ospedale Regina Elena, Roma

Unknown

RECRUITING

Ospedale Giaccone, Palermo